Multispanning Membrane Polypeptide Stabilization via Random Mutagenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for working with multispanning membrane proteins face challenges such as high hydrophobicity, conformational flexibility, low stability, and low expression levels, leading to difficulties in experimentation and handling.
Innovation Solution
A method and platform are developed to generate modified multispanning membrane polypeptides with improved properties through random mutagenesis, using selection markers to select for stably folded proteins, and expressing them in host cells to enhance properties like stability and antigenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If random mutagenesis and selection markers are used to improve protein stability, then stability and antigenicity are enhanced, but the process complexity and time required increase
Solution Approach 1:
The patent applies preliminary action by pre-modifying the multispanning membrane polypeptide with stabilizing mutations and fusion partners before the actual screening process. This preliminary modification ensures that the protein maintains stable folded conformations throughout subsequent experimental steps, eliminating the need for complex stabilization measures during screening and reducing overall process complexity.
Solution Approach 2:
The patent uses fusion partners and selection markers as intermediary elements that facilitate protein stabilization and detection. These intermediaries act as molecular bridges that enhance protein stability while providing selectable phenotypes, thereby simplifying the overall process by converting a complex stabilization problem into a manageable selection process.
2Reliability
If fusion partners and selection markers are added to enhance protein detection and stability, then antigenicity and stability improve, but the molecular weight and structural complexity increase
Solution Approach 1:
The patent employs reporter genes that produce detectable signals (analogous to color changes in TRIZ terminology) to indicate successful protein expression and folding. These reporters provide reliable detection mechanisms without significantly increasing molecular complexity, as they function as independent modular units that can be easily attached to the target protein.
Solution Approach 2:
The patent segments the protein construct into distinct functional modules: the multispanning membrane polypeptide domain, fusion partners for stabilization, and selection markers for detection. This segmentation allows each component to perform its specific function independently, reducing overall molecular complexity while enhancing detection reliability and stability.
3Ease of operation
If modified polypeptides are generated through mutagenesis to improve handling characteristics, then stability and antigenicity enhance, but the time and resources required for library generation increase
Solution Approach 1:
The patent applies parameter changes by systematically varying mutagenesis conditions, selection marker types, and fusion partner configurations to optimize protein stability and handling characteristics. By pre-establishing optimal parameters through preliminary experiments, the actual library generation process is accelerated, reducing time loss while maintaining improved handling properties.
Solution Approach 2:
The patent performs preliminary mutagenesis and selection to identify stable protein variants before generating the full screening library. This preliminary action creates a pre-validated set of stable polypeptides that can be rapidly propagated and screened, significantly reducing the time required for library generation while ensuring improved handling characteristics from the outset.
Data Source
AI summary
Disclosed herein are methods, platform, antibodies, vaccines, constructs, and kits for generating a modified multispanning membrane polypeptide. In some instances, also disclosed herein are methods, platform, antibodies, vaccines, constructs, and kits for generating a modified ion channel polypeptide. In some cases, further disclosed herein are methods, platform, antibodies, vaccines, constructs, and kits for generating a modified GPCR.